Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: Current status and future directions

Drugs

Volumn 68, Issue 8, 2008, Pages 1019-1028

  Mandava, Pitchaiah ^a   Thiagarajan, Perumal ^a   Kent, Thomas A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Abciximab, therapeutic use; Eptifibatide, therapeutic use; Stroke, treatment; Tirofiban, therapeutic use

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; SDZ GPI 562; TICLOPIDINE; TIROFIBAN; UROKINASE;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MICROCIRCULATION; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; RECANALIZATION; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

ACUTE DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STROKE; TYROSINE;

EID: 43749099194     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00001     Document Type: Review

References (62)

1. 3. J Clin Invest 2005; 115: 3363-9
2. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75: 1383-95
3. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004; 104: 1606-15
4. Xiao T, Takagi J, Coller BS, et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004; 432: 59-67
5. Murugappan S, Shankar H, Kunapuli SP. Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost 2004; 30: 411-8
6. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-35
7. Gawaz M, Neumann FJ, Ott I, et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-37
8. Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996; 76: 166-72
9. Andrews RK, Berndt MC. Platelet physiology and thrombosis. Thromb Res 2004; 114: 447-53
10. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75
11. Cura FA, Bhatt DL, Lincoff M, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 2000; 102: 28-34
12. Casserly IP, Topol EJ. Glycoprotein IIb/IIIa antagonists: from bench to practice. Cell Mol Life Sci 2002; 59: 478-500
13. Coller BS, Folts JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 1989; 80: 1766-74
14. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-43
15. Béguin S, Kumar R, Keularts I, et al. fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999; 93: 564-70
16. Pancioli AM, Brott TG. Therapeutic potential of platelet glyco-protein IIb/IIIa receptor antagonists in acute ischaemic stroke: scientific rationale and available evidence. CNS Drugs 2004; 18: 981-8
17. Warkentin TE, Kelton JG. Platelet life cycle: qualitative disorders. In: Handin RI, editor. Blood. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 983-1047
18. Choudhri TF, Hoh BL, Zerwes H-G, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 1998; 102: 1301-10
19. Abumiya T, Fitridge R, Mazur C, et al. Integrin αIIbβ3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000; 31: 1402-10
20. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation 1997; 95: 1755-9
21. Collet JP, Montalescot G, Lesty C, et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-31
22. Marciniak SJ, Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 2002; 87: 1020-5
23. Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 1997; 88: 137-46
24. Shuaib A, Yang Y, Nakada MT, et al. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy. J Cereb Blood Flow Metab 2002; 22: 215-22
25. Eckert B, Koch C, Thomalla G, et al. Aggressive therapy with intravenous abciximab and intra-arterial rtPA and additional PTA/stenting improves clinical outcome in acute vertebrobasilar occlusion: combined local fibrinolysis and intravenous abciximab in acute vertebrobasilar stroke treatment (FAST). Results of a multicenter study. Stroke 2005; 36: 1160-5
26. Qureshi AI, Harris-Lane P, Kirmani JF, et al. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study. Neurosurgery 2006; 59: 789-96
27. Pancioli AM, for the CLEAR Trial Investigators. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke (the CLEAR stroke trial): final results form tier I and II [abstract]. Stroke 2008; 39: 531
28. Seitz RJ, Meisel S, Moll M, et al. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology 2004; 62: 2110-2
29. Straub S, Junghans U, Jovanovic V, et al. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 2004; 35: 705-9
30. Mangiafico S, Celllerini M, Nencini P, et al. Intravenous tirofiban with intra-arterial urokinase and mechanical thrombolysis in stroke: preliminary experience in 11 cases. Stroke 2005; 36: 2154-8
31. Ding G, Jiang Q, Zhang L, et al. Analysis of combined treatment of embolic stroke in rat with r-tpa and a GPIIB/IIIa inhibitor. J Cereb Blood Flow Metab 2005; 25: 87-97
32. The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000; 31: 601-9
33. Abciximab Emergent Stroke Treatment Trial Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005; 36: 880-90
34. Adams HP, Effron MB, Torner J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial. Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87-99
35. Mitsias PD, Lu M, Silver B, et al. MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window. Neurology 2005; 65: 612-5
36. Mandava P, Kent TA. Intra-arterial therapies for acute ischemic stroke. Neurology 2007; 68: 2132-9
37. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288: 2130-5
38. Dubois CL, Belmans A, Granger CB, et al. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. J Am Coll Cardiol 2003; 42: 1178-85
39. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percuataneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569-78
40. Cheung RT, Ho DS. Fatal hemorrhagic transformation of acute cerebral infarction after the use of abciximab. Stroke 2000; 31: 2526-7
41. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7
42. Coller BS, Scudder LE. Inhibitions of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985; 66: 1456-9
43. Tamberella MR, Bhatt DL, Chew DP, et al. Relation of platelet inactivation with intravenous glycoprotein iib/iiia antagonists to major bleeding (from The GOLD Study). Am J Cardiol 2002; 89: 1429-31
44. Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-30
45. Lee KY, Heo JH, Lee SI. Rescue treatment with abciximab in acute ischemic stroke. Neurology 2001; 56: 1585-7
46. Heo JH, Lee KY, Kim SH. Immediate reocclusion following a successful thrombolysis in acute ischemic stroke: a pilot study. Neurology 2003; 60: 1684-7
47. Mandava P, Lick SD, Rahman MA, et al. Initial safety experience of abciximab and heparin for acute ischemic stroke. Cerebrovasc Dis 2005; 19: 276-8
48. Mandava P, Kent TA. Reversal of dense signs predicts recovery in acute ischemic stroke. Stroke 2005; 36: 2490-2
49. Day JRS, Malik IS, Weerasinghe A, et al. Distinct yet complimentary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. Heart 2004; 90: 794-9
50. Smith WS, Sung G, Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39: 1205-12
51. Steinhubl SR, Talley DJ, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8
52. Mandava P, Anderson J, Thiagarajan P, et al. Platelet aggregation unit inhibition with abciximab in acute ischemic stroke [abstract]. Stroke 2008; 39: 603
53. Steinhubl SR, Kottke-Marchant K, Moliterno DJ. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. Circulation 1999; 100: 1977-82
54. Shaltoni H, Martin-Schild S, Khaja A, et al. A phase I study of eptifibatide in acute ischemic stroke. American Academy of Neurology 59th Annual Meeting; 2007 Apr 28-May 5; Boston (MA)
55. Shaltoni H, Martin-Schild S, Khaja A, et al. Eptifibatide for deteriorating lacunar infarcts. American Academy of Neurology 59th Annual Meeting; 2007 Apr 28-May 5; Boston (MA)
56. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-65
57. Futrell N. Lacunar infarction: embolism is the key. Stroke 2004; 35: 1778-9
58. Norrving B. Lacunar infarction: embolism is the key. Against. Stroke 2004; 35: 1779-80
59. Junghans U, Seitz RJ, Aulich A, et al. Bleeding risk of tirofiban, a nonpeptide GPIIb/IIIa platelet receptor antagonist in progressive stroke: an open pilot study. Cerebrovasc Dis 2001; 12: 308-12
60. Stone GW, Gersh BJ. Facilitated angioplasty: paradise lost. Lancet 2006; 367: 543-6
61. National Institutes of Health. ReoPro and retavase to treat acute stroke [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00046293 [Accessed 2007 Jul 20]
62. Saver JL. Time is brain-quantified. Stroke 2006; 37: 263-6